Drug Approval | October 19, 2021
MSN Labs launches drug for diabetes management
The company claims that its Empagliflozin tablets are the most affordable in India
The company claims that its Empagliflozin tablets are the most affordable in India
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
U.S. FDA to decide whether to authorize a booster dose in the coming days
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Subscribe To Our Newsletter & Stay Updated
